CD274 and lung carcinoma: Although PD-1 or PD-L1 immune checkpoint inhibitor therapy significantly improves the survival rate of lung cancer patients, only about 20–40% of NSCLC patients benefit from them, with a minority of patients showing durable responses to treatment, suggesting innate or acquired resistance to immunotherapy [9].